scholarly journals ANALISIS HUBUNGAN KADAR GULA DARAH PUASA DENGAN KADAR KOLESTEROL HIGH DENSITY LIPOPROTEIN (HDL) PADA PASIEN DIABETES MELLITUS TIPE 2 DI RSUP SANGLAH

2016 ◽  
Vol 4 (2) ◽  
Author(s):  
Nyoman Jirna
Keyword(s):  
Blood Sugar ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Fasting Blood Sugar ◽  
Cholesterol Levels ◽  
Sugar Levels ◽  
Dm Type 2 ◽  
The Relationship

Abstract Diabetes mellitus (DM) is a group of metabolic diseases with characteristic hyperglycemia that happen by abnormal secretions of insulin, insulin action, or both. The condition of insulin resistance in DM type 2 cause abnormal lipid metabolism that indicated by increase or decrease levels of lipid fraction in plasma, include increase levels of Very Low Density Lipoprotein (VLDL) or triglycerides, decrease levels of High Density Lipoprotein (HDL), and formed small dense Low Density Lipoprotein (LDL). The purpose of this study is to determine the relationship between the fasting blood sugar levels with HDL cholesterol levels in patients with DM type 2. The method use an analytical study with cross sectional design. Sampling examined as many as 35 samples by purposive sampling. The relationship between fasting blood sugar levels with HDL cholesterol levels is analyzed by Pearson Product Moment Correlation test. Based on the result concluded that there is a relationship between fasting blood sugar levels with HDL cholesterol levels in patients with DM type 2 in RSUP Sanglah with significant value sig=0,030 (sig

scholarly journals Pioglitazone-Mediated Changes in Lipoprotein Particle Composition Are Predicted by Changes in Adiponectin Level in Type 2 Diabetes

2012 ◽  
Vol 97 (1) ◽  
pp. E110-E114 ◽  
Author(s):  
Susan Sam ◽  
Steven Haffner ◽  
Michael H. Davidson ◽  
Ralph D'Agostino ◽  
Alfonso Perez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Particle Size ◽  
Adiponectin Level ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Vldl Particle ◽  
The Relationship

Context: In animal and observational studies, adiponectin is associated with lipoprotein risk factors for cardiovascular disease. Objective: We analyzed data from a randomized clinical trial to evaluate the relationship between changes in adiponectin to changes in lipoprotein risk factors after an intervention that alters adiponectin levels. Design and Setting: Adiponectin levels were measured at baseline and follow-up, as were lipoprotein risk factors for cardiovascular disease, at academic medical centers and ambulatory care centers. Patients and Other Participants: Participants included 361 men and women with type 2 diabetes. Intervention: Intervention included randomization to treatment with glimepiride or pioglitazone for 72 wk. Main Outcome Measure: The relationship of treatment-related differences in adiponectin level to treatment-related differences in lipoprotein cardiovascular risk factors at 72 wk was evaluated. Results: Pioglitazone led to an increase in adiponectin compared with glimepiride. Compared with baseline, pioglitazone treatment at 72 wk led to an increase in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and a decrease in very-low-density lipoprotein (VLDL) particle size and LDL particle number. Glimepiride treatment more modestly decreased LDL particle number and increased LDL particle size. At 72 wk, there were significant treatment group differences for HDL, LDL, and VLDL particle size, and triglyceride and HDL cholesterol level. The increase in adiponectin predicted treatment-related improvement for triglyceride and HDL cholesterol level and LDL and HDL particle size. Conclusion: Increased adiponectin contributed to treatment-related benefit in lipoprotein cardiovascular disease risk factors in obese diabetic subjects treated with pioglitazone. These results provide support for a model that mechanistically links changes in adiponectin level to changes in lipoprotein composition in humans.

scholarly journals Influence of Dyslipidemia on the Quality of Sexual Life in Women in the Menacme using a Combined Oral Contraceptive

2016 ◽  
Vol 38 (12) ◽  
pp. 600-608
Author(s):  
Rodolfo Strufaldi ◽  
Luciano Pompei ◽  
Marcelo Steiner ◽  
César Fernandes
Keyword(s):  
Sexual Function ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Sexual Life ◽  
Cholesterol Levels ◽  
Reproductive Life ◽  
The Relationship

Purpose Female sexual dysfunction is a complex and common condition that affects women, and the relationship between sexual function and dyslipidemia is poorly studied. This study aims to assess this relationship in the reproductive life women in the menacme who use combined oral contraceptives (COCs). Methods A total of 49 healthy women who were sexually active received COC pills that contained ethinylestradiol 30 mcg (EE30) plus levonorgestrel 150 mcg (LNG150). The women were divided into two groups according to their lipid profiles. Dyslipidemia was defined as a high-density lipoprotein (HDL) level < 50 mg/dL or a low-density lipoprotein (LDL) level > 130 mg/dL. Sexual function was assessed using the Female Sexual Function Index (FSFI) Questionnaire. Lipid and lipoprotein parameters were obtained at baseline and after the sixth cycle. Results After six cycles of the COCs, the total cholesterol and LDL cholesterol levels in the women with a LDL level > 130 mg/dL decreased by 14.7% and 22.1% respectively. In the women with a HDL level < 50 mg/dL at baseline, the HDL level increased by 15.5% at the end of the study. The arousal and orgasm domains and the FSFI total scores significantly increased in women with and without dyslipidemia. The desire and satisfaction domains increased only in the group without dyslipidemia at the end of the treatment period. Conclusions The EE30/LNG150 formulation increased the sexual function and it was only positively correlated with the HDL cholesterol level. These data indicated a low correlation between sexual function and the changes in the lipid and lipoprotein metabolism.

scholarly journals Correlation of Fasting Blood Glucose With IL-6 Levels in Type-2 Diabetes Mellitus Ethnic Minangkabau

BioScience ◽  
2018 ◽  
Vol 2 (1) ◽  
pp. 11
Author(s):  
Elsa Yuniarti ◽  
Syam Syamsurizal ◽  
Yuni Ahda ◽  
Puja Delfi Sonata
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Sugar ◽  
Fasting Blood Sugar ◽  
Control Group ◽  
Type 2 Dm ◽  
Sugar Levels ◽  
Dm Type 2

Diabetes Mellitus (DM) Type 2 is a metabolic disorder disease characterized by an increase in blood sugar (hyperglycemia) due to decreased insulin secretion by pancreatic beta cells or intrusion of insulin function. Hyperglycemia tends to cause oxidative stress where free radical formation exceeds the body's antioxidant defense system resulting in microvascular and macrovascular disorders. Some ethnic groups have a tendency to develop type 2 diabetes mellitus because of differences in diet, lifestyle and physical activity. In addition, ethnicity is also suspected to affect the levels of IL-6. This study aims to determine the correlation of fasting blood sugar levels with IL-6 levels in type 2 diabetes mellitus ethnic Minangkabau. This research is cross sectional comparative research design. The subjects of two groups: DM type 2 and control group (non-DM) who went to the Polyclinic of State University of Padang, Minangkabau ethnic and each consisted of 35 people. Blood glucometer examination with blood sample and IL-6 measurement using ELISA technique with serum sample. Fasting blood sugar levels in patients with Type 2 DM Minangkabau ethnic average 286.2 ± 80.46 mg / dl while non DM 101.26 ± 9.70 mg / dl. Mean IL-6 levels in type 2 DM patients were 16.23 ± 30.12 pg / ml while non-DM of 3.41 ± 1.91 pg / ml was an increase of about 4.7 in patients with type 2 DM Compared to non-ethnic minority of Minangkabau with p value <0,05. The result of research that have been done there is a positive correlation between fasting blood sugar level with IL -6 in patients with Type 2 DM Minangkabau ethnic with r value = 0,44 at p <0.05 which means interpretation of medium correlation strength. Keywords: Type 2 DM, IL-6, ethnic Minangkabau

scholarly journals EFFECT OF TETRAHYDROCURCUMIN ON LIPID PROFILES IN STREPTOZOTOCIN–NICOTINAMIDE INDUCED TYPE 2 DIABETES MELLITUS

2021 ◽  
Vol 21 (No 1) ◽  
Author(s):  
Pidaran Murugan
Keyword(s):  
Low Density Lipoprotein ◽  
Elevated Serum ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Diabetic Rats ◽  
Low Density ◽  
Cholesterol Levels ◽  
Antihyperlipidemic Activity ◽  
Type 2 Diabetic

Hyperlipidemia is one of the major risk factors of cardiovascular complication in diabetes. A study was undertaken to evaluate the antihyperlipidemic activity of tetrahydrocurcumin (THC). Oral administration of THC (80mg/ kg bodyweight) to streptozotocin-nicotinamide induced diabetic rats for 45 days, significantly reduced the elevated serum very low density lipoprotein (VLDL) and low density lipoprotein (LDL) – cholesterol levels and significantly increased the serum high-density lipoprotein (HDL)-cholesterol. THC showed a better effect when compared with curcumin. Results of the present study indicate that THC showed antihyperlipidemic effect in addition to its antidiabetic effect in type 2 diabetic rats

Jumpstarting Health With a 15-Day Whole-Food Plant-Based Program

2021 ◽  
pp. 155982762110063
Author(s):  
Susan M. Friedman ◽  
Carol Hee Barnett ◽  
Robert Franki ◽  
Bruce Pollock ◽  
Beth Garver ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Blood Sugar ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Food Plant ◽  
Fasting Blood Sugar ◽  
Average Weight ◽  
Low Density ◽  
Average Drop

The 15-day Jumpstart was developed as an evidence-based, affordable, standardized, replicable, and scalable program, designed to demonstrate quickly to patients that changing what they eat can improve their health. The program was designed using the principles of the self-determination theory of motivation and personality. Patients were instructed to eat an Esselstyn-compliant, whole-food plant-based diet consisting of vegetables, fruits, whole grains, and legumes. Of the 389 participants in the program from September 2018 to February 2020, average weight loss was 5.8 pounds (7.3 for those whose body mass index was >30), average systolic blood pressure drop was 6.8 points (16.8 points for those with systolic blood pressure >140), average drop in cholesterol was 26 points (44 points for those with a cholesterol >200), average drop in low-density lipoprotein was 19 points (33 points for those with a low-density lipoprotein >100), and average drop in fasting blood sugar was 5.1 points (28.4 points for those starting in the diabetic range); P value was <.005 for fasting blood sugar and <.001 for all other comparisons. A 15-day program that helps patients adopt an Esselstyn-style whole-food plant-based diet, through education, individualized medical feedback, social support, and facilitated small group work, rapidly improves health.

scholarly journals Pengaruh Pelayanan Kefarmasian di Rumah pada Pasien Diabetes Melitus Tipe 2 di Puskesmas Wilayah Kota Yogyakarta

2020 ◽  
Vol 10 (2) ◽  
pp. 126
Author(s):  
Nur Rasdianah ◽  
Suwaldi Martodiharjo ◽  
Tri Murti Andayani ◽  
Lukman Hakim
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Medication Adherence ◽  
Glycemic Control ◽  
Blood Sugar ◽  
Fasting Blood Sugar ◽  
Level Of Knowledge ◽  
Sugar Levels

The increasing prevalence of diabetes mellitus (DM) in Indonesia requires participation of all parties including pharmacists. This study aims to determine the impact of the implementation of home pharmacy service guidelines for patients with type 2 diabetes mellitus on the level of knowledge, medication adherence, therapeurical satisfaction and glycemic control. This study used a quasi-experimental design with one group pre-test and post-test design involving 37 patients with type 2 diabetes mellitus who met the requirements of inclusion and exclusion criterias. The Diabetes Knowledge Questionnaire (DKQ-24) and the Diabetes Medication Satisfaction Tool (DMSAT) were used for collecting the data. Patient adherence was measured using a pillcount method and fasting blood sugar levels (FSB) data were obtained from the laboratory results. The study was conducted in two community health centers and patient’s home in the Yogyakarta Municipality area. The data were analysed using Wilcoxon and Spearman test. The results showed the change of the level of knowledge, medication adherence, therapeutic satisfaction and glycemic control before and after intervention of pharmacy services at home. The average decreasing of fasting blood sugar levels 17.09 mg/dL ± 1.43

Dyslipidaemia

2019 ◽  
pp. 33-48
Author(s):  
Heinz Drexel
Keyword(s):  
Cardiovascular Disease ◽  
Randomized Clinical Trials ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Epidemiological Studies ◽  
Residual Risk ◽  
Atherosclerotic Cardiovascular Disease ◽  
Cholesterol Levels

Lipid metabolism has gained cardiological interest only after statins were demonstrated to reduce cardiovascular disease in secondary and primary prevention. Therefore, this chapter first introduces the physiological and atherogenic properties of lipoproteins, before focusing on interventions. Both the efficacy and safety of statins have been proven in numerous randomized clinical trials. Because there is a considerable residual risk in statin-treated patients, additional approaches have been investigated. The focus is now on further reductions in low-density lipoprotein (LDL) cholesterol levels. First, high-intensity statin regimens were shown to reduce residual risk. Subsequently, ezetimibe was demonstrated, for the first time, to have a beneficial effect as a non-statin lipid intervention. More recently, inhibitors of the enzyme PCSK9 have demonstrated a very high efficacy in reducing LDL cholesterol levels. Although the causality of LDL for atherosclerotic cardiovascular disease has been proven in epidemiological studies, including Mendelian randomization studies, as well as interventional trials, adherence to statins and other therapies is far from optimal. In contrast, interventions to increase high-density lipoprotein (HDL) cholesterol levels could not proven to have further benefits when combined with statins.

scholarly journals Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes

2019 ◽  
Vol 12 ◽  
pp. 117955141986681 ◽  
Author(s):  
Yuka Kamijo ◽  
Hideto Ishii ◽  
Tomohiko Yamamoto ◽  
Kunihisa Kobayashi ◽  
Hiroyuki Asano ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Sglt2 Inhibitor ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Sglt2 Inhibitors ◽  
Diabetic Patients ◽  
Lipoprotein Subfractions ◽  
Cholesterol Levels

Introduction: Recently, the sodium-glucose cotransporter2 (SGLT2) inhibitor empagliflozin has been shown to lower cardiovascular risk among diabetic patients. It is intriguing that some SGLT2 inhibitors have been found to increase low-density lipoprotein (LDL) cholesterol levels, while the relevance to high-density lipoprotein (HDL) cholesterol is unknown. Although the inhibitory effect of SGLT2 inhibitors on glucose reabsorption may accelerate compensatory lipid metabolism and subsequently reduce body weight and affect the lipid profile, much remains unclear about this mechanism. Therefore, we conducted this study to investigate in detail how canagliflozin affects lipoprotein fractions including LDL and HDL subclasses. Materials and Methods: This study is a multicenter prospective study. The participants were patients with 22 type 2 diabetes (60.7 ± 11.6 years, 59.1% of men) who had HbA1c ⩾ 7.0% and consented to participate in the study. They were administered 100 mg canagliflozin orally once per day. Biochemistry test and cholesterol levels of 20 lipoprotein fractions (G1-G20) using high performance liquid chromatography methods were examined before and after 12 weeks of treatment period. Results: Significant decreases were observed in the participants’ body weight (69.7 to 67.9 kg, P < .001), systolic blood pressure (129.3 to 119.5 mm Hg, P < .01), and HbA1c (8.5% to 7.4%, P < .001). Cholesterol levels in the 20 lipoprotein fractions increased for very large HDL (G14, G15) and large HDL (G16) ( P < .05). Conclusions: Reduction in body weight, improvement of blood glucose levels, and increases in very large HDL and large HDL subclasses were observed after canagliflozin treatment. These beneficial changes might contribute to subsequent suppression of cardiovascular outcomes.

Paradoxical Hypercholesterolemia in an Otherwise Healthy Adult Man

2019 ◽  
Author(s):  
Peter A Mcpherson
Keyword(s):  
Cholesterol Level ◽  
Total Cholesterol Level ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Red Yeast Rice ◽  
Transfer Protein ◽  
Cholesterol Levels ◽  
Red Yeast ◽  
High High Density Lipoprotein

AbstractHypercholesterolemia is characterized by serum cholesterol levels greater than 5 mmol per L. However, the distribution of cholesterol among lipoprotein classes has a significant bearing on diagnosis: high–low-density lipoprotein (LDL) cholesterol suggests familial hypercholesterolemia, whereas high–high-density lipoprotein (HDL) cholesterol is associated with hyperalphalipoproteinemia. On routine screening, a 23-year-old man presented with a total cholesterol level of 7.6 mmol per L but was subsequently found to have an HDL cholesterol level of 5.6 mmol per L. The clinical picture was confounded by his use of red yeast rice extract, a popular health supplement with hypolipidemic effects. In this case individual, the use of red yeast rice extract caused a hyperlipidemic state, ostensibly through downregulation of cholesteryl ester transfer protein. This case emphasizes the extended role of laboratory medicine in complex cases of hyperlipidemia.

Sign in / Sign up

Export Citation Format

Share Document